SMARCAL1 loss and alternative lengthening of telomeres (ALT) are enriched in giant cell glioblastoma.

Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
Jacqueline A Brosnan-CashmanChristopher M Heaphy

Abstract

Subsets of high-grade gliomas, including glioblastoma (GBM), are known to utilize the alternative lengthening of telomeres (ALT) pathway for telomere length maintenance. However, the telomere maintenance profile of one subtype of GBM-giant cell GBM-has not been extensively studied. Here, we investigated the prevalence of ALT, as well as ATRX and SMARCAL1 protein loss, in a cohort of classic giant cell GBM and GBM with giant cell features. To determine the presence of ALT, a telomere-specific fluorescence in situ hybridization assay was performed on 15 cases of classic giant cell GBM, 28 additional GBMs found to have giant cell features, and 1 anaplastic astrocytoma with giant cell features. ATRX, SMARCAL1, and IDH1 protein status were assessed in a proportion of cases by immunohistochemistry and were compared to clinical-pathologic and molecular characteristics. In the overall cohort of 44 cases, 19 (43%) showed evidence of ALT. Intriguingly, of the ALT-positive cases, only 9 (47.4%) displayed loss of the ALT suppressor ATRX by immunohistochemistry. Since inactivating mutations in SMARCAL1 have been identified in ATRX wild-type ALT-positive gliomas, we developed an immunohistochemistry assay for SMARCAL1 protein expression usin...Continue Reading

References

Jan 27, 2000·Cell·D Hanahan, R A Weinberg
Sep 4, 2003·Proceedings of the National Academy of Sciences of the United States of America·Yutong XueWeidong Wang
Oct 29, 2004·Molecular and Cellular Biology·Anthony J Cesare, Jack D Griffith
Mar 31, 2010·Nature Reviews. Genetics·Anthony J Cesare, Roger R Reddel
Jul 24, 2010·Proceedings of the National Academy of Sciences of the United States of America·Peter W LewisC David Allis
Mar 23, 2011·Stem Cells·David C SilvestreFrançois D Boussin
Jul 2, 2011·Science·Christopher M HeaphyAlan K Meeker
Sep 6, 2011·The American Journal of Pathology·Christopher M HeaphyAlan K Meeker
Mar 27, 2013·Proceedings of the National Academy of Sciences of the United States of America·Patrick J KillelaHai Yan
Jun 15, 2013·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Malak AbedalthagafiArie Perry
Jul 20, 2014·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Taemin OhAndrew T Parsa
May 23, 2015·Oncotarget·Christine E NapierRoger R Reddel
Oct 8, 2015·Brain Pathology·Ji Eun OhHiroko Ohgaki
Nov 19, 2015·Proceedings of the National Academy of Sciences of the United States of America·Lisa A PooleDavid Cortez
Feb 3, 2016·Cell Reports·Kelli E CoxRachel Litman Flynn
May 29, 2018·Nature Communications·Bill H DiplasHai Yan
Jun 23, 2018·JAMA Oncology·Quinn T OstromJill S Barnholtz-Sloan
Dec 12, 2018·Nature Medicine·Fulvio D'AngeloAntonio Iavarone
Apr 23, 2019·World Neurosurgery·Michael C JinErqi L Pollom
Aug 30, 2019·Acta Neuropathologica Communications·Fausto J RodriguezChristopher M Heaphy

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.